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Abstract
Leber congenital amaurosis (LCA) is an infantile-onset form of inherited retinal degeneration
characterized by severe vision loss1, 2. Two-thirds of LCA cases are caused by mutations in 17
known disease genes3 (RetNet Retinal Information Network). Using exome sequencing, we
identified a homozygous missense mutation (c.25G>A, p.Val9Met) in NMNAT1 as likely disease-
causing in two siblings of a consanguineous Pakistani kindred affected by LCA. This mutation
segregated with disease in their kindred, including in three other children with LCA. NMNAT1
resides in the previously identified LCA9 locus and encodes the nuclear isoform of nicotinamide
mononucleotide adenylyltransferase, a rate-limiting enzyme in nicotinamide adenine dinucleotide
(NAD+) biosynthesis4, 5. Functional studies showed the p.Val9Met mutation decreased NMNAT1
enzyme activity. Sequencing NMNAT1 in 284 unrelated LCA families identified 14 rare
mutations in 13 additional affected individuals. These results are the first to link an NMNAT
isoform to disease and indicate that NMNAT1 mutations cause LCA.
Inherited retinal diseases such as LCA represent a heterogeneous group of early-onset
blindness that are characterized by progressive dysfunction and death of the rod and cone
retinal photoreceptor cells6. Despite more than 180 different inherited retinal disease genes
having already been identified, the genetic etiology for 40–50% of inherited retinal disease
cases remains uncertain7 (RetNet). Additional loci have been identified with as yet
unidentified disease genes, such as the LCA9 locus mapped to chromosome 1p36 (ref. 4).
Identifying the genetic basis of inherited retinal diseases is essential to guide potential
therapies, as highlighted by the recent success of clinical gene therapy trials for RPE65-
related LCA8–12. Here we employed whole exome sequencing in a large consanguineous
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tPakistani pedigree, including five children affected with LCA who did not have mutations in
known LCA genes.
Two Pakistani siblings, an 11-year-old girl and her 3-year-old brother (Fig. 1a, Family 047,
subjects IV-1 and IV-3), initially presented to the Ophthalmology-Genetics Clinic at the
Children’s Hospital of Philadelphia for evaluation of LCA based on severe vision
impairment, congenital nystagmus and no detectable (<10 µV) retinal function by full-field
electroretinography (ERG) testing in early infancy (see Supplementary Note for additional
clinical details). Both children also had global developmental delay, non-verbal autism with
stereotypies, hypotonia with joint hypermobility and dysmorphic facies. Severe to profound
bilateral sensorineural hearing loss was present in the 11-year-old proband (IV-1) as well as
in her 8-year-old brother (IV-2), who had a normal eye exam and normal development but
clinical features of a suspected mucolipidosis (Supplementary Note). Their parents were first
cousins who were visually and developmentally normal (Fig. 1a, subjects III-4 and III-5).
Notably, the parents’ siblings had married one another (Fig. 1a, subjects III-3 and III-6) and
together had two children with similar visual and non-verbal autism phenotypes as the
proband (subjects IV-7 and IV-8) as well as one child with isolated LCA (IV-6). Clinical
genetic diagnostic testing identified a homozygous mutation in GJB2 (c.71G>A, p.Trp24*)
as the cause of sensorineural hearing loss in subject IV-1, but no mutation was identified in
any of the known LCA genes (Supplementary Note).
To search for the genetic cause of LCA in this family, we performed whole exome
sequencing of the nuclear family of the 11-year-old proband (Fig. 1a, subjects IV-1, IV-2,
IV-3, III-4 and III-5). A homozygous mutation of biparental inheritance that was shared by
both affected children but not by their sibling with normal visual acuity was postulated to be
their most likely mode of LCA disease given known consanguinity. We identified a total of
113 non-synonymous variants in 86 genes that met these criteria (Supplementary Fig. 1).
Four of these variants were rare or novel based on dbSNP 132, 1000 Genomes Project data
or NHLBI Exome Sequencing Project (ESP) data13, 14. The genes harboring these four
variants had known retinal expression based on mouse retina RNA-seq analyses15. Only one
of these variants was predicted to damage protein function by SIFT, Polyphen2 and other
programs, which was c.25G>A (p.Val9Met) in NMNAT1 (refs. 16–20). Sanger sequencing
of the c.25G>A variant in NMNAT1 validated its segregation with the LCA phenotype in
the original nuclear kindred and in the proband’s similarly affected cousins, including one
individual with isolated LCA (Fig. 1a,b). This variant was not present in 501 controls or any
public databases13, 14.
No clearly pathogenic mutations were identified to be the likely cause of developmental
delay, non-verbal autism, hypotonia and dysmorphic facies in family members IV-1, IV-3,
IV-7 and IV-8. These presentations likely have a separate genetic etiology from the LCA
and deafness in this family because individual IV-6 has LCA alone, individual IV-2 has
deafness alone and additional NMNAT1 mutations were identified in individuals with non-
syndromic LCA, as described below.
To determine if NMNAT1 mutations cause LCA in other families, we sequenced NMNAT1
in 56 LCA probands (evaluated by M.J.F. and E.A.P. at The Children’s Hospital of
Philadelphia (CHOP) or by E.A.P. and E.L.B. at the Massachusetts Eye and Ear Infirmary
(MEEI)). We found rare compound heterozygous mutations in NMNAT1 that segregated
with disease in family 007, in which the proband was a 5-year-old girl with isolated LCA
and no family history of disease (Fig. 1c and Table 1). We also identified compound
heterozygous variants in NMNAT1 that segregated with disease in family 053, in which the
proband was a 20-year-old man with LCA (Fig. 1d and Table 1). The four NMNAT1
variants identified in these subjects were not identified in 501 control samples.
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tTo investigate the frequency of NMNAT1 mutations in LCA, we screened additional patient
populations of varying ethnic backgrounds. This included 248 additional probands
ascertained at Institut de la Vision in Paris, LV Prasad Eye Hospital (LVPEI) in India and
University College London (UCL). These analyses identified homozygous or compound
heterozygous mutations in NMNAT1 in 11 additional LCA families (Table 1 and
Supplementary Fig. 2). All of the mutations detected are rare, and all of them with the
exception of the one encoding the p.Glu257Lys variant were predicted to be damaging by
PolyPhen 2 and/or SIFT (Table 1). None of the NMNAT1 variants identified in these
subjects were identified by Sanger sequencing in 501 control samples. Review of available
clinical information for individuals in whom NMNAT1 mutations were identified as the
cause of their LCA (Supplementary Note) indicated that the majority have atrophic macular
lesions (Fig. 2).
NMNAT1 encodes a rate-limiting enzyme that generates NAD+ both in a biosynthetic
pathway from nicotinic acid mononucleotide (NaMN) and in a salvage pathway from
nicotinamide mononucleotide (NMN) (Supplementary Fig. 3)21. Three functionally non-
redundant mammalian NMNAT isoforms encoded by different genes have been identified
within distinct cellular compartments, where NMNAT1, NMNAT2 and NMNAT 3 localize,
respectively, to the nucleus, Golgi complex and mitochondria5, 22. The mitochondrial
isoform, NMNAT3, regenerates NAD+ for cellular energetics, whereas NMNAT1 is
involved in nuclear NAD+ homeostasis necessary for both DNA metabolism and cell
signaling5. Of interest, Nmnat1 is the principle component of the mouse Wallerian
degeneration (Wlds) fusion protein, which also includes a 70 amino acid N-terminal
sequence from the Ube4b multi-ubiquitination factor, and has been shown to have
neuroprotective activity23. Nmnat1 homozygous knockout mice are embryonic lethal,
whereas heterozygous Nmnat1 knockout mice have normal development24. Loss of nmnat in
Drosophila photoreceptors leads to photoreceptor cell degeneration25.
We assessed the potential deleterious effects of the novel missense variants p.Val9Met,
p.Arg66Trp and p.Arg237Cys on the NMNAT1 protein. These altered residues are located
in conserved regions of the protein (Supplementary Fig. 4) and are predicted to damage
NMNAT1 protein structure and stability by several prediction programs26, 27. All three of
these mutant proteins showed correct nuclear localization and normal expression levels
following expression of recombinant NMNAT1 protein in heterologous cells
(Supplementary Fig. 5a,b). In addition, the p.Val9Met mutant protein correctly localized to
the nucleus of a fibroblast cell line obtained from the LCA proband in family 047 (Fig. 1a,
subject IV-1 and Supplementary Fig. 5c)22.
Given the normal nuclear localization and expression of the mutant NMNAT1 proteins, we
postulated that the deleterious effect of the p.Val9Met, p.Arg66Trp and p.Arg237Cys
variants might be on NMNAT1 enzymatic function. We therefore measured the NAD+
biosynthetic activity of purified recombinant NMNAT1 wild-type and mutant proteins (Fig.
3a). Despite variability in enzyme rates observed between experimental days, the p.Val9Met
protein NMNAT1 activity was reproducibly and significantly decreased compared to same-
day wild-type values (63.4% median reduction, interquartile range 31.4–88.7 , Wilcoxon
rank sum test, P = 0.0015). The enzyme activity of the p.Arg66Trp protein was also
significantly decreased (99.5% median reduction, interquartile range 0.01–0.11, Wilcoxon
rank sum test, P = 0.0014). The enzyme activity of the p.Arg237Cys mutant protein showed
only marginally reduced activity (by 18.9%, interquartile range 41.1–90.1, Wilcoxon rank
sum test, P = 0.034) (Fig. 3a), raising the question of how this mutation causes disease. It
has been observed that NMNAT1 forms functional homo-oligomers and that amino acids
234–238 participate in these protein interactions5. To evaluate whether the pathogenic effect
of the p.Arg237Cys variant could relate to its location in a region of NMNAT1 involved in
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tprotein multimerization, we measured NMNAT1 activity in recombinant protein purified
from cells co-transfected with constructs for both the p.Arg66Trp and p.Arg237Cys variants
that were identified in family 007. We observed notably reduced enzyme activity (to 18% of
wild-type control rate; data not shown) in the combined protein preparation. Additional
studies using extracts from the p.Val9Met proband’s fibroblast cells (Fig. 1a, subject IV-1)
showed a decrease in total cellular NMNAT enzyme activity by 73% (two-tailed t test P =
0.016) relative to wild-type control (Fig. 3b). These data suggest the pathogenic effects of
these mutations relate at least in part to significantly reduced NMNAT1 enzyme activity. It
will be of interest to investigate the function of the mutant NMNAT1 proteins in retinal
cells, given the isolated retinal phenotype of this disease.
The total NAD+ concentration of human cells has many contributing determinants21, 28. We
measured NAD+ in the LCA proband’s fibroblast cell line (Fig. 1a, subject IV-1) to
determine whether the p.Val9Met variant in the nuclear-localized NMNAT1 protein
significantly impacted total cellular NAD+ content. Fibroblasts from the LCA proband
(subject IV-1) showed a 16% decrease in NAD+ content relative to wild-type controls,
although this difference was not significant (two-tailed t test P = 0.067; Fig. 3c). These data
suggest that the reduction in NMNAT1 enzyme activity caused by the p.Val9Met variant
may be sufficient to impact total cellular NAD+ content.
Cellular NAD+ concentrations can be directly increased by nicotinic acid, which requires
NMNAT activity for its conversion to NAD+ (Supplementary Fig. 3)29. We therefore asked
whether the cellular NAD+ levels in the NMNAT1 p.Val9Met mutant fibroblasts (subject
IV-1) was altered by treatment with 10 mM nicotinic acid for 24 hours. Importantly, while
nicotinic acid significantly increased the total cellular NAD+ content by 53% in control cells
(two-tailed t test P = 0.021), it had no effect on NAD+ content of the LCA proband’s
fibroblasts (Fig. 3c; two-tailed t test P > 0.05). The failure of nicotinic acid to increase the
NAD+ content in NMNAT1 p.Val9Met mutant fibroblasts provides further evidence that
they have a significant deficiency in their cellular NMNAT enzymatic activity.
In summary, we report here the first instance of any disease association with an NMNAT
isoform5. NMNAT1 mutations cause LCA and are the likely pathogenic basis for disease
previously linked to the LCA9 locus, although the family originally linked to this locus was
not available for analysis in this study4 (Chris Inglehearn, personal communication).
Through exome sequencing in a consanguineous Pakistani LCA kindred and subsequent
Sanger sequencing of NMNAT1 in 285 unrelated LCA probands, we identified mutations in
14 unrelated families (14/285 = 4.9 % of unrelated cases). This work suggests that mutations
in NMNAT1 are a relatively common cause of LCA3. However, since the cohorts of
individuals used for these studies are enriched for subjects without mutations in known LCA
disease genes, the proportion of all LCA cases caused by NMNAT1 mutations is likely to be
over-estimated by these data.
The identification of NMNAT1 as an LCA disease gene raises the intriguing question of
how mutations in a widely expressed NAD+ biosynthetic protein lead to a retina-specific
phenotype. The data presented suggest that the retinal degeneration phenotype observed in
individuals with NMNAT1 mutations results from decreased NAD+ biosynthetic activity.
This hypothesis is consistent with findings from studies of the Wlds protein in mice, which
demonstrated that the neuroprotective effect of the Wlds protein requires both the Ube4b
component and an enzymatically active NMNAT1 portion of the chimeric protein30.
However, it appears that in some systems, such as Drosophila, nmnat alone has a
neuroprotective role that may be independent of its NAD+ biosynthetic activity25, 31. Thus,
it remains to be determined if retinal degeneration caused by mutations in NMNAT1 results
primarily from the loss of a potentially novel neuroprotective effect of NMNAT1 or to a
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tpreviously unappreciated role of NAD+-mediated signaling in retinal health and disease. In
either case, NMNAT1 mutations represent a novel pathophysiologic cause of LCA, further
underscoring the genetic heterogeneity of inherited retinal diseases3, 6. We postulate that
pharmacologic and/or genetic therapies directed at restoring cellular NAD+ homeostasis in
retinal cells may offer a therapeutic strategy for NMNAT1-related LCA.
ONLINE METHODS
Subject recruitment and clinical evaluations
The clinical study was approved by the institutional review boards of The Massachusetts
Eye and Ear Infirmary, Children’s Hospital of Philadelphia, CPP Ile de France V, LV Prasad
Eye Hospital, and University College London, and conformed to the tenets of the
Declaration of Helsinki. Informed consent was obtained from the participants. Complete
ophthalmic and clinical genetic evaluations of members of family 047 (subjects IV-1, IV-1,
IV-3), family 007 (subject II-2), and family 053 were performed by M.J.F. and E.A.P. in the
Ophthalmology-Genetics Clinic at the Children’s Hospital of Philadelphia.
Exome sequencing
Exome capture was performed using Agilent Technologies SureSelectXT 50 Mb All Exon
Targeted Enrichment Kit as described in the kit manual36. The resulting exome capture
libraries were 2 × 101 bp paired-end sequenced on an Illumina HiSeq 2000 Next-Generation
Sequencing system using v2.5 SBS chemistry with average flowcell lane cluster densities of
~800 K/mm2. One exome sample was analyzed per flowcell lane to obtain a minimum 10x
read depth for 92–95% of the targeted exome.
Exome data analyses
BWA (version 0.5.9-r16) was used to align the sequence reads to the human reference
genome GRCh37 downloaded from the 1000 Genomes Project website (http://www.
1000genomes.org/)37. Samtools (version 0.1.12 or r859) was used to remove potential
duplicates (with rmdup command), and make initial SNP and indel calls (with pileup
command)38. A custom program was developed and used to further refine the SNP and indel
calls. The custom program uses a false discovery rate approach to adjust raw base counts at
a candidate position after Benjamini and Hochberg correction based on quality values of all
bases39. A coverage depth cutoff of 10X is then applied. The fraction of a variant base has to
be between 0.25–0.75 to be called heterozygous and above 0.75 to be called homozygous.
Resulting variant calls were annotated using our custom human bp codon database. This
database maps each base position in the human reference genome, based on Ensembl
Release 65 gene annotations, to its corresponding, if any, transcripts, genes, codons,
encoded amino acids, and translation frames. Additional annotations of each variant call
were provided using data sets downloaded from the 1000 Genomes Project website (http://
www.1000genomes.org/), the NHLBI Exome Sequencing Project Exome Variant Server
(http://evs.gs.washington.edu/EVS/) and the UCSC Genome Browser (http://
genome.ucsc.edu/). These annotations include allele frequencies, SIFT and PolyPhen
predictions, and phastCons conservation scores16, 17. Custom scripts were also developed
and used to identify candidate variants that fit different filtering criteria, such as genetic
models.
NMNAT1 PCR amplification, Sanger sequencing and genotype confirmation
Subjects in families 007, 047 and probands from other families with LCA were selected for
Sanger sequence analysis using primers to amplify all four exons and intron-exon
boundaries of NMNAT1 (Supplementary Table 1). PCR products were sequenced with the
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tABI PRISM Big Dye Terminator Cycle Sequencing V2.0 Ready Reaction kit on ABI 3100
or 3730 DNA analyzers (Applied Biosystems). To genotype the members of family 047, the
relevant PCR product was digested with AcuI, which cuts the wild-type but not mutant
sequence.
Human fibroblast culture and nicotinic acid treatment
Skin biopsies were performed on two siblings with LCA and their parents (Fig 1a, subjects
IV-1, IV-3, III-4, III-5) following informed consent per approved CHOP IRB protocol
(#08-6177, M.J.F.). Fibroblast cell lines were established in the CHOP CytoGenomics
Laboratory, and subsequently maintained in T75 flasks in a 37°C CO2 incubator per
standard protocol in DMEM (Gibco) with 20% FBS, 2 mM L-glutamine, 1 mM pyruvate
and 50 µg/mL uridine (Calbiochem). Cells were grown to confluence prior to undergoing
functional analyses. Cells were treated in T75 flasks with 10 mM nicotinic acid (Sigma) for
24 hours, trypsinized, washed twice with Hank’s Balanced Salt Solution (Gibco), and flash
frozen in liquid nitrogen for HPLC analysis.
Cell culture
CHO-K1 and wild-type mIMCD3 cell lines were purchased from American Type Culture
Collection (ATCC). The mIMCD3 cells were maintained in DMEM:F12 media
supplemented with 10% FBS and 0.5 mM sodium pyruvate. CHO cell culture was
performed in F12 medium supplemented with 10% FBS. Transfection was performed with
Lipofectamine 2000 (Invitrogen) and cells were processed for immunocytochemistry 48–72
h after transfection. Human skin fibroblast cells obtained from two LCA siblings (Fig 1a,
subjects IV-1 and IV-3) and their parents (Fig 1a, subjects III-IV and III-V) were maintained
in Medium 106 (Invitrogen) with low serum growth supplement, and grown to confluence
prior to undergoing immunofluorescence and immunoblot analyses.
Immunofluorescence analyses
Cells were fixed in 4% paraformaldehyde, permeabilized, and then blocked with 1% bovine
serum albumin (BSA) and 0.2% Triton X-100 in PBS, as previously described40. The cells
were then stained with anti-V5 antibody (Invitrogen) followed by Alexa Fluor 555–
conjugated goat anti-mouse IgG (Invitrogen)40. Fluorescent signals were visualized using a
Nikon Eclipse fluorescent microscope.
Western blotting
Total cell lysates from CHO cells transfected with pCAG V5-NMNAT1-IRES-EGFP
plasmid were separated on a precast NuPAGE 4–12% Bis-Tris Gel (Invitrogen) and
transferred to a PVDF membrane, as previously described41. The membrane was probed
with anti-V5, anti-human NMNAT1 (1:500; Novus Biologicals) or β-actin (Santa Cruz
Biotechnology) followed by IRDye (LI-COR) goat anti-mouse IgG and antibody binding
detected with an Odyssey infrared imager (LI-COR).
Recombinant protein production and purification
Human NMNAT1 cDNA was amplified by reverse transcription polymerase chain reaction
(RT-PCR) from a cDNA clone (OpenBiosystem), cloned into a pENTR/D-TOPO entry
vector (Invitrogen), and fully sequence-verified. The coding sequence was moved by
recombination to a Gateway compatible destination expression vector modified to contain
N-terminal V5 (pCAG-V5-IRES-EGFP) or Flag (pCAG-Flag-IRES-EGFP) epitope tags in
frame. Plasmid DNA was purified using the EndoFree plasmid maxi kit (Qiagen).
Recombinant NMNAT1 (with Flag-tag) expressed in CHO cells was purified using a FLAG
M Purification kit (Sigma) for subsequent enzyme activity assay.
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NMNAT activity was measured by high performance liquid chromatography (HPLC)
quantitation of the reaction product, NAD+. The assay mixture contained 1.5 mM ATP, 1
mM nicotinamide mononucleotide (NMN), 10 mM MgCl2 in 25 mM Tris-HCl (pH 7.4), and
the appropriate amount of enzyme sample (typically, 20 or 40 µL) to achieve a final volume
of 0.2 mL. The reaction was started by the addition of the substrate NMN. After incubation
for 10, 30, or 120 min at 37 °C, a 40 µL aliquot of the reaction mixture was withdrawn and
added to 20 µL of ice-cold 1.2 M PCA containing 20 mM EDTA and 0.15% sodium
metabisulfite to stop the reaction. After a 15 min incubation at 4°C, the mixture was
centrifuged for 10 min at 16,000 × g in a Beckman microcentrifuge. A 55 µL aliquot of the
supernatant was further neutralized by the addition of 20 µL of ice-cold 1 M K2CO3 and
centrifuged again. The supernatant was isolated and stored at −80°C until HPLC analysis.
Sample preparation for HPLC analyses of NAD+
Harvested cells were rinsed with Hank’s balanced salt solution twice and centrifuged at
2,150 × g for 5 min. The cell pellet was resuspended with argon-bubbled 20 mM Tris-HCl
pH 7.4 for analysis of the oxidized dinucleotides including NAD+. The cell suspension was
extracted with 4 volumes of argon-bubbled ice-cold 1.2M perchloric acid (PCA) containing
20 mM EDTA and 0.15% sodium metabisulfite. After vortexing, the suspension was placed
on ice for 15 minutes and then centrifuged at 16,000 × g for 10 min. The supernatant was
neutralized with 1 M potassium carbonate and centrifuged to remove insoluble material. The
pellet from the PCA extraction was used for protein estimation. Samples were stored at
−80°C and subjected to HPLC analysis.
HPLC conditions for analyses of NAD+
Separation of the oxidized dinucleotides was carried out on a C18 column (5 µm, 4.6 × 250
mm, Adsorbosphere XL C18 90Å) preceded by a guard column at 40°C. Flow rate was set
at 0.5 mL/min. The mobile phase was initially 100% of mobile phase A (0.1 M sodium
phosphate buffer, pH 6.0, containing 3.75% methanol). The methanol was linearly increased
with mobile phase B (0.1 M sodium phosphate buffer, pH 6.0, containing 30% methanol),
increasing to 50% over 15 minutes. The column was washed after each separation by
increasing mobile phase B to 100% for 5 min. UV absorbance was monitored at 260 and 340
nm with Shimadzu SPD-M20A. Pertinent peak areas were integrated by the LabSolution
software from Shimadzu, and quantified using standard curves.
Statistical analyses
For comparison of activity rates of purified, recombinant NMNAT1 proteins relative to
wild-type, rates were normalized by the mean rate of the wild-type protein analyzed on the
same day to account for variation in the absolute enzyme activity rates on different analysis
dates. The significance of group differences was evaluated using a non-parametric Wilcoxon
rank sum test in SAS 4.3 due to skewness observed in the data and small sample size. For
measurements of cellular NMNAT activity and NAD+ levels, statistical comparisons
between groups were performed using Student’s 2-tailed t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
Pedigrees of three LCA kindreds evaluated at The Children’s Hospital of Philadelphia in
whom mutations were identified in NMNAT1. (a) Family 047. Consanguineous Pakistani
kindred in which homozygous NMNAT1 mutations were identified in five children with
LCA by whole exome sequencing with Sanger sequencing validation. M1 = NMNAT1
mutation (c.25G>A, p.Val9Met). M2 = GJB2 mutation (c.71G>A , p.Trp24*). A
representative sequence trace for the M1 mutation is shown. Exome sequencing confirmed
the presence of the p.Trp24* homozygous mutation in GJB2 in the two children (IV-1 and
IV-2) who were affected with sensorineural hearing loss. Sanger sequencing verified that
this mutation also segregated with the hearing loss phenotype in their larger kindred. Subject
IV-2 had no identifiable pathogenic mutations within any of the known mucolipidosis
disease genes. (b) The members of family 047 were genotyped by PCR amplification of
exon 2 of NMNAT1, followed by digestion of the PCR products with AcuI to distinguish
the wild-type from the mutant sequence. The genotyping data illustrate the segregation of
the mutant NMNAT1 (M1) allele only in the five children with LCA in generation IV,
whereas the four unaffected parents of these children in generation III carry both the mutant
and wild-type alleles, and their three children with normal vision harbor only the wild-type
allele. Individuals III-4, III-5, IV-1, IV-2 and IV-3 were clinically evaluated by M.J.F. and
E.A.P.; individuals III-3, III-6 and V-4 to IV-7 were not clinically evaluated by the authors.
(c) Family 007. A single LCA proband was identified by Sanger sequencing of NMNAT1 to
harbor compound heterozygous mutations c.196C>T (p.Arg66Trp) and c.709C>T (p.
Arg237Cys). (d) Family 053. A single LCA proband was identified by Sanger sequencing of
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tNMNAT1 to harbor compound heterozygous mutations c.205A>G (p.Met69Val) and c.
769G>A (p.Glu257Lys). The ‘+’ or ‘M’ below each symbol represents a wild-type or
specific mutant allele. Squares and circles indicate male or female, respectively, and
numbers within symbols indicate multiple offspring of a given gender. Slashes depict
deceased individuals. Colors within symbols indicate affected individuals, with phenotypes
defined in the pedigree key.
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Retinal image from individual with LCA due to mutations in NMNAT1. Composite fundus
image of the right eye of subject II-1, LVPEI family LCA-100, showing pallor of the optic
disc, attenuation of the retinal blood vessels, pigment disruption and atrophic changes in the
macula (arrow), and scattered pigment clumping in the peripheral retina. The optic disc is
approximately 1.75 mm in diameter.
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NMNAT1 enzyme activity and cellular NAD+ content. (a) The NAD+ biosynthetic activity
of wild-type, p.Val9Met, p.Arg66Trp, p.Arg237Cys and p.Trp169Ala purified recombinant
NMNAT1 proteins was measured as described. Boxplots display activity measurements of
independently generated and measured replicate protein preparations. The length of the box
represents 25th to 75th inter-quartile range, the interior horizontal line represents the median,
the interior cross represents the mean, and vertical lines issuing from the box extend to the
minimum and maximum values of the analysis variable. The p.Trp169Ala mutant had
complete loss of NMNAT1 enzyme activity (n = 6; P = 0.0014), as was previously
reported32. The p.Val9Met mutant protein NMNAT1 enzyme activity was significantly
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treduced at 37% of wild-type control (n = 7; P = 0.0015). The p.Arg237Cys mutant protein
showed an average of 81% of wild-type NMNAT1 activity (n = 6; P = 0.034). The
p.Arg66Trp mutant protein showed complete loss of enzyme activity (n = 6; P = 0.0014),
although we were not able to achieve effective purification of the Flag-tagged version of the
p.Arg66Trp mutant protein (Supplementary Fig. 6) despite its clearly normal expression and
nuclear localization in CHO and IMCD3 cells (Supplementary Fig. 5). Further experiments
will be needed to determine if the Flag-tagged p.Arg66Trp protein is unstable to
purification. *P < 0.05 and **P < 0.01 determined by non-parametric Wilcoxon rank sum
test. (b) Total cellular NMNAT enzyme activity was measured in whole cell extracts of
fibroblasts from a healthy control and the LCA proband from Family 047 (subject IV-1)
who was homozygous for the p.Val9Met NMNAT1 variant. The p.Val9Met mutant cells had
27% of total cellular NMNAT NAD+ synthetic activity relative to control cells (two-tailed t
test P = 0.016; n = 6 for wild-type, n = 5 for LCA proband cells). (c) Cellular NAD+ levels.
Total cellular NAD+ content was quantified by HPLC in control and LCA proband IV-1
(Fig. 1a) fibroblasts at baseline and following 10 mM nicotinic acid treatment for 24 hours.
NAD+ content in fibroblast cells from the LCA proband (p.Val9Met) was decreased by 16%
relative to those from a wild-type control (P = 0.067). Nicotinic acid treatment significantly
increased NAD+ content in control cells (P < 0.05) but had no effect on NAD+ content in the
proband’s cells (P > 0.05). n = 7 for both cell lines without treatment, n = 6 for control cells
treated with nicotinic acid, and n = 4 for IV-1 cells treated with nicotinic acid. For b and c,
bars indicate mean and standard error. *P < 0.05.
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P
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b
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.
P
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P
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.
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v
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P
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.
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v
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P
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c
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.
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v
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c
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.
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.
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v
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P
r
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B
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h
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n
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:
 
H
u
m
-
V
a
r
 
s
c
o
r
e
 
P
r
D
,
 
p
r
o
b
a
b
l
y
 
d
a
m
a
g
i
n
g
;
 
P
o
D
,
 
p
o
s
s
i
b
l
y
 
d
a
m
a
g
i
n
g
;
 
B
,
 
b
e
n
i
g
n
.
b
S
I
F
T
:
 
D
,
 
d
a
m
a
g
i
n
g
;
 
T
,
 
t
o
l
e
r
a
t
e
d
.
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i
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i
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c
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b
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c
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c
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p
r
e
d
i
c
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c
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p
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p
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.
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h
e
 
r
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r
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l
u
2
5
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y
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a
r
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c
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.
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.
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c
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r
i
a
n
t
 
i
s
 
p
a
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F
u
t
u
r
e
 
e
m
p
i
r
i
c
 
s
t
u
d
i
e
s
 
o
f
 
t
h
e
 
e
f
f
e
c
t
 
o
f
 
t
h
i
s
 
m
u
t
a
t
i
o
n
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n
 
p
r
o
t
e
i
n
 
f
u
n
c
t
i
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n
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e
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i
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b
e
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e
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e
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e
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t
h
o
g
e
n
i
c
i
t
y
 
o
f
 
t
h
i
s
 
N
M
N
A
T
1
 
v
a
r
i
a
n
t
.
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